Stocks Perrigo Co


  • Prosecutors said the trades enabled SAC Capital to make $275 million, making it the most lucrative insider trading case ever charged in the United States. The $10 million class action accord, which requires court approval, follows earlier deals with U.S. authorities in which SAC Capital agreed to pay $1.8 billion and plead guilty following investigations...

  • DEALS-Year of the mega deal unlikely to be repeated Monday, 21 Dec 2015 | 8:52 PM ET

    While the number of announced deals globally declined from 2014 by 2.1 percent to 39,687, deal volume rose 40.8 percent to a record $4.6 trillion, according to preliminary Thomson Reuters data, as big companies pursued their dream matches. This year's mega deals included many with long-expected operational efficiencies, such as brewer Anheuser-Busch...

  • Mylan to buy back $1 bln in stock Monday, 16 Nov 2015 | 11:53 AM ET

    Nov 16- Generic Drugmaker Mylan NV plans to buy back shares worth up to $1 billion, after Perrigo Co Plc'S shareholders spurned its $26 billion hostile bid. The buyback program expires on Aug. 27, 2016, Mylan said in a statement on Monday. Perrigo shareholders rejected Mylan's bid on Friday, ending the Netherlands- based generic drug maker's seven-month pursuit of...

  • Nov 13- Drugmaker Mylan NV's $26 billion hostile bid for Perrigo Co Plc failed on Friday, putting an end to the ongoing saga, which started more than seven months ago. April 8, 2015: Mylan offers to buy Perrigo for about $29 billion in cash and stock in a move that some analysts suggested was an effort to help fend off a $40 billion acquisition by larger rival Teva...

  • Nov 12- Generic drug maker Mylan NV's $26 billion hostile bid for peer Perrigo Company Plc looked unlikely to succeed late on Thursday, a few hours before it was set to expire, according to people familiar with the matter. If confirmed, the outcome would represent a major victory for Perrigo's defiant Chief Executive Joseph Papa, and a bitter blow to Mylan's...

  • WASHINGTON, Nov 3- Mylan received U.S. antitrust approval for its hostile bid for Irish-based generic drugmaker Perrigo Co under the condition Mylan sells seven drugs to Alvogen Group Inc, the Federal Trade Commission said on Tuesday. Netherlands- based Mylan made an offer for Perrigo in April, which was rejected, and went hostile in September.

  • *Court denies Perrigo motion for injunction on tender offer. Oct 30- Mylan NV, embroiled in an increasingly bitter takeover attempt for fellow drugmaker Perrigo Co Plc, posted a better-than-expected quarterly profit on Friday as sales of its generic drugs increased in North America and Europe. Dublin- based Mylan offered to buy Perrigo in April in a...

  • Oct 30- Mylan NV, which has made a hostile bid for Perrigo Co Plc, posted a better-than-expected quarterly profit as sales of its generic drug increased in North America and Europe. The company also said on Friday a U.S. district court had denied Perrigo's motion for a preliminary injunction to block the closing of any tender offer related to its bid.

  • Mylan revenue rises 29 percent Friday, 30 Oct 2015 | 7:10 AM ET

    Oct 30- Mylan NV, which has made a hostile bid for Perrigo Co Plc, posted a 29 percent rise in quarterly revenue as demand for its generic drugs increased in North America and Europe. Dublin- based Mylan's revenue rose to $2.70 billion in the third quarter ended Sept. 30 from $2.08 billion a year earlier. Net income attributable to shareholders fell to $428.6 million,...

  • Oct 28- Mylan NV said an Israeli district court has ruled against target Perrigo Company Plc's attempt to block Mylan's listing on the Tel Aviv Stock Exchange. A Tel Aviv listing will strengthen Netherlands- based Mylan's efforts to get Perrigo shareholders on its side. Perrigo has repeatedly urged its shareholders not to accept Mylan's $25 billion hostile...

  • Martoma's lawyer told the 2nd U.S. Circuit Court of Appeals in New York that under the ruling, a doctor who prosecutors say provided information about a drug trial's outcome could not be found to have done so for an illegal quid pro quo. But Arlo Devlin-Brown, a prosecutor, said evidence showed Martoma paid the doctor, Sidney Gilman, $70,000 to get the tip, which...

  • *Perrigo to cut 800 jobs, or 6 pct of workforce. Oct 22- Perrigo Co Plc said it would lay off 6 percent of its global workforce and buy back shares worth $2 billion to boost earnings, as the generic drug maker looks to convince investors to rebuff Mylan NV's hostile bid. Mylan, which first made a bid for Perrigo in April, went hostile in September, offering $75 in cash and 2.3...

  • *Perrigo shares down about 3 pct; Mylan shares down 4.4 pct. Shares of Perrigo- which also said it would cut about 800 jobs, or 6 percent of its workforce- were down about 3.6 percent in morning trading. Mylan has been repeatedly spurned by Perrigo since April, forcing the generic drugmaker to take its buyout offer directly to Perrigo's shareholders.

  • Perrigo also said it is beginning the process of selling its U.S. Netherlands- based Mylan has offered $75 in cash and 2.3 of its shares for each Perrigo share, a combination worth $169.05 based on Mylan's closing price on Wednesday of $40.89. Perrigo's shares were up 2 percent at $159.71 in premarket trading.

  • *Fed Chair Janet Yellen is scheduled to speak at 3:00 p.m. ET at a conference in St. Louis, along with St. Louis Fed President James Bullard. *New York Fed President William Dudley is scheduled to speak before the Securities Industry and Financial Markets Association in New York at 8:30 a.m..

  • Perrigo rejects Mylan's bid Thursday, 17 Sep 2015 | 7:00 AM ET
    Perrigo rejects Mylan's bid

    Perrigo rejected Mylan's $27 billion public offer, saying it substantially undervalues the company.

  • MYL shareholders approve PRGO deal Friday, 28 Aug 2015 | 9:00 AM ET
    MYL shareholders approve PRGO deal

    Mylan shareholders back proposed Perrigo purchase.

  • M&A close to record in Q2 amid mega deals Tuesday, 30 Jun 2015 | 6:54 AM ET

    Mergers and acquisitions worldwide in the second quarter of 2015 almost matched the record set in the second quarter of 2007.

  • Teva poised to raise its stake in Mylan: Report Wednesday, 3 Jun 2015 | 7:07 AM ET
    Mylan headquarters Canonsburg, Pennsylvania

    Teva Pharmaceutical is looking to buy more shares in Mylan, positioning itself for a possible legal challenge to the generics drugmaker.

  • Perrigo expands its drug portfolio Tuesday, 2 Jun 2015 | 10:00 AM ET
    Perrigo expands its drug portfolio

    Perrigo acquires OTC portfolio from GlaxoSmithKline for undisclosed sum.